Form 4: Century Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock on May 6, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Gregory Russotti, the Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock on May 6, 2024.
• The sale was executed under a Rule 10b5-1 trading plan adopted on January 9, 2024.
• The shares were sold at a weighted average price of $3.1238.
• The price range for individual transactions was between $3.00 and $3.29.
• Following the transaction, Russotti directly owns 292,319 shares and indirectly owns 92,773 shares through the Gregory Russotti 2021 Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale under a pre-arranged trading plan. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Future Outlook

NA

Industry Context

This is a routine disclosure of an insider stock sale. It's common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading. The impact on the stock is likely to be minimal unless the market interprets it as a lack of confidence by the executive.

Comparison to Industry Standards

• Executive stock sales are common in publicly traded companies, especially in the biotech industry where stock options and grants are a significant part of compensation.
• Comparable companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also see regular Form 4 filings from their executives.
• The size of this transaction (5,000 shares) is relatively small compared to the total outstanding shares of Century Therapeutics and is unlikely to have a significant impact on the stock price.
• The use of a 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations, similar to what executives at other biotech firms employ.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but is unlikely to be significant given the relatively small number of shares sold and the use of a 10b5-1 trading plan.
• There is no direct impact on employees, customers, suppliers, or creditors.

Key Dates